These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 8806006

  • 1. Salmon calcitonin in the prevention of bone loss at perimenopause.
    Arnala I, Saastamoinen J, Alhava EM.
    Bone; 1996 Jun; 18(6):629-32. PubMed ID: 8806006
    [Abstract] [Full Text] [Related]

  • 2. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 3. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A.
    Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
    [Abstract] [Full Text] [Related]

  • 4. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.
    Flicker L, Hopper JL, Larkins RG, Lichtenstein M, Buirski G, Wark JD.
    Osteoporos Int; 1997 Oct; 7(1):29-35. PubMed ID: 9102059
    [Abstract] [Full Text] [Related]

  • 5. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS, Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators.
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [Abstract] [Full Text] [Related]

  • 6. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
    Ofluoglu D, Karadag-Saygi E, Canbulat C, Gunduz OH, Kul-Panza E, Akyuz G.
    Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
    [Abstract] [Full Text] [Related]

  • 7. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
    Rizzoli R, Sigaud A, Azria M, Herrmann FR.
    Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study.
    Overgaard K, Lindsay R, Christiansen C.
    Clin Ther; 1995 Jan; 17(4):680-5. PubMed ID: 8565031
    [Abstract] [Full Text] [Related]

  • 10. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, de Longueville M, Franchimont P.
    Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
    [Abstract] [Full Text] [Related]

  • 11. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
    Ellerington MC, Hillard TC, Whitcroft SI, Marsh MS, Lees B, Banks LM, Whitehead MI, Stevenson JC.
    Calcif Tissue Int; 1996 Jul; 59(1):6-11. PubMed ID: 8661976
    [Abstract] [Full Text] [Related]

  • 12. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
    Wang SX, Li H.
    Chin Med J (Engl); 2008 Jul 20; 121(14):1280-4. PubMed ID: 18713548
    [Abstract] [Full Text] [Related]

  • 13. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F, Colak O, Armagan O, Alatas O, Oner C.
    Rheumatol Int; 2005 Nov 20; 26(1):21-9. PubMed ID: 15688191
    [Abstract] [Full Text] [Related]

  • 14. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
    Reginster JY, Denis D, Deroisy R, Lecart MP, De Longueville M, Zegels B, Sarlet N, Noirfalisse P, Franchimont P.
    J Bone Miner Res; 1994 Jan 20; 9(1):69-73. PubMed ID: 8154311
    [Abstract] [Full Text] [Related]

  • 15. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
    Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D.
    Am J Med; 2000 Sep 20; 109(4):267-76. PubMed ID: 10996576
    [Abstract] [Full Text] [Related]

  • 16. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis.
    Adachi JD, Bensen WG, Bell MJ, Bianchi FA, Cividino AA, Craig GL, Sturtridge WC, Sebaldt RJ, Steele M, Gordon M, Themeles E, Tugwell P, Roberts R, Gent M.
    Br J Rheumatol; 1997 Feb 20; 36(2):255-9. PubMed ID: 9133941
    [Abstract] [Full Text] [Related]

  • 17. Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy.
    Peichl P, Rintelen B, Kumpan W, Bröll H.
    Gynecol Endocrinol; 1999 Feb 20; 13(1):7-14. PubMed ID: 10368793
    [Abstract] [Full Text] [Related]

  • 18. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.
    Chesnut CH, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, Azria M, Kriegman A, Olson M, Eriksen EF, Mindeholm L.
    J Bone Miner Res; 2005 Sep 20; 20(9):1548-61. PubMed ID: 16059627
    [Abstract] [Full Text] [Related]

  • 19. Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.
    Gonnelli S, Cepollaro C, Montomoli M, Gennari L, Montagnani A, Palmieri R, Gennari C.
    Clin Endocrinol (Oxf); 1997 Jan 20; 46(1):55-61. PubMed ID: 9059558
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.